此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Clinical Study to Collect Real-wordt Data on Safety and Clinical Performance of the VCFix Spinal System for Treatment of Vertebral Compression Fractures of (Suspected) Osteoporotic Origin. (EXPAND-US)

2026年11月4日 更新者:Amber Implants B.V.

A Prospective, Multicenter, Post-Market Clinical Study Collecting Real-World Data of the VCFix Spinal System in Stand-Alone Configuration for Vertebral Augmentation (EXPAND-US)

This study is designed as a prospective, post-market, multi-center, single-arm study to collect real-world data of the VCFix Spinal System used in US clinical practice.

Approximately 5 centers in the US will enroll subjects with VCF in a non-randomized fashion, and VCFix will be used within its cleared purpose and indications for use.

The study has been designed to be methodologically compatible with the EU EXPAND (CIP-VS02-EU) study, thereby aiming for the pooling of data to the EU study. Data pooling will be pursued only as a sensitivity analysis if pre-specified similarity criteria are met. The US study provides meaningful real-world evidence regardless of pooling feasibility.

The targeted patient population, assessment schedule, and study endpoints are therefore similar to those of the EU EXPAND study.

研究概览

研究类型

观察性的

注册 (估计的)

30

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • New York
      • New York、New York、美国、10467
        • 招聘中
        • Montefiore Medical Center
        • 接触:
          • Research Administrator
          • 电话号码:(718) 920-6202
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73104
        • 尚未招聘
        • University of Oklahoma Health Campus
        • 接触:
          • Research Project Manager
          • 电话号码:(405) 271-8001
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19107
        • 尚未招聘
        • Rothman Orthopaedics
        • 接触:
          • Clinical Research Coordinator
          • 电话号码:(484) 335-2910

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

21年 至 85年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Adult patients undergoing treatment with the VCFix Spinal System as part of standard clinical care for vertebral compression fractures. The study will enroll patients treated according to routine clinical practice and will collect real-world evidence on clinical outcomes, radiographic outcomes, and patient-reported outcomes following treatment.

描述

Inclusion Criteria:

  • 1. Subject is ≥ 21 to ≤ 85 years old. 2.

Single vertebral fracture which meets all of the following criteria:

  • Type A fractures from AO spine classification (compression injuries);
  • Vertebral fracture located in the thoracic and lumbar regions of the spine
  • Fracture age < 6 weeks or fractures with anatomic signs of reducibility (based on radiographic evidence as well as patient history)
  • Vertebral fracture shows an estimated height loss in the anterior or mid third of the vertebral body (VB) of at least 10% but not more than 60% based on radiographic evidence
  • Target VB has appropriate anatomy, i.e. suitable pedicle diameter, pedicle length and chord length that would allow for selection of correct implant size, as described in the IFU and based on axial MRI/CT scan before surgery 3. Subject is diagnosed with, or has a suspected diagnosis of, severe osteoporosis, including low trabecular bone quality , and/or an oversized vertebral body as compared to implant size (e.g. relatively small pedicle requiring smaller implant size than desired for vertebral body size and/or fracture characteristics and location) 4. Subject has a NPRS back pain score of ≥5 5. Subject is a candidate for surgical intervention based on investigator opinion 6. Subject has a body Mass Index (BMI) < 35 7. Subject is mentally capable of complying with trial protocol requirements for the duration of the study 8. Subject can understand the risks and benefits of participating in the study and is able to provide written informed consent

Exclusion Criteria:

  1. Neoplasms with posterior involvement and/or presence of a mass within the spinal canal

  2. Non-mobile fractures (i.e., fracture is not recent (>6 weeks), bone marrow edema or fluid or empty cleft are not visible in radiographic imaging, or fracture mode does not allow for fracture reduction in craniocaudal direction).

  3. Spondylolisthesis > Grade 1 at target vertebral body(s)

  4. Local kyphotic angle > 30°

  5. Any pre-existing vertebral fracture prior to the index fracture

  6. Previous spine surgery, balloon kyphoplasty or vertebroplasty, for any vertebral fracture

  7. Subjects that require anterior stabilization of the index fracture

  8. Fracture to the pedicle based on radiographic evaluation

  9. Spinal cord compression or canal compromise requiring decompression

  10. Severe back pain due to causes other than acute fracture with NPRS score > 5

  11. The subject has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)

  12. Pain due to any other condition that requires daily narcotic (opiates or opioids) medication

  13. Pre-existing neurological deficit, radiculopathy or myelopathy

  14. Pre-existing condition or significant co-morbidity:

    1. Uncontrolled diabetes (HbA1c >8%)
    2. Severe cardiopulmonary deficiencies
    3. Any other condition that would impact study outcome in the opinion of the investigator
  15. Irreversible coagulopathy or bleeding disorder

  16. Contraindications to both MRI and Computed Tomography (CT) imaging

  17. Concurrent participation in another clinical study which could potentially interfere with the outcome of this study

  18. A life expectancy less than the study duration or undergoing palliative care

  19. Subject non-ambulatory prior to fracture Allergy to any components of the device/instruments used during the procedure

  20. Allergy to any components of the device/instruments used during the procedure

  21. Active or incompletely treated infection of the vertebral column or active systemic infection, including unresolved urinary tract infection

  22. Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfecta, Paget's disease, etc.)

  23. Any evidence of alcohol or drug abuse

  24. Ongoing long-term steroid therapy (steroid dose ≥30 mg /day for >3 months)

  25. The subject is currently on anti-cancer therapy or anti-HIV therapy

  26. Pregnancy or subjects with child-bearing potential that are unwilling to use contraception throughout the study duration.

  27. Patient known to be involved in medical litigation including Workmen's Compensation prior to the surgery

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Implant of the VCFix device per IFU

Patients with a (suspected) diagnosis of severe osteoporosis and a single vertebral compression fracture

The distinguishing features of this inetrvention reside in: 1. In situ adjustment and maintenance of the height and angle of the device that allows expansion of the fractured VB in the cranio-caudal direction to realign the vertebral endplates and correct kyphosis. 2. The complex titanium perforated structure with optimized surface roughness that allows possible bone attachment, thereby permitting natural healing of the bone and potentially providing more stability to the device and the treated vertebra over time. 3. The ability to connect the posterior to the anterior column of the spine through the pedicle screw component of the VCFix implant, therefore improving the biomechanical load distribution and consequently the ability to stabilize more severe fractures.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of serious adverse events (SAEs) related to the device and/or investigational procedure (safety)
大体时间:1 month

Incidence of serious adverse events (SAEs) related to the device and/or investigational procedure within 30 days post-procedure. This includes SAEs resulting from mechanical malfunction, structural compromise, device failure, or loss of intended function, as well as events representing deviations from the device's intended medical purpose.

1 month
Vertebral fracture-related pain as assessed by the Numeric Pain Rating Scale (NPRS)
大体时间:6 months

Difference in vertebral fracture-related pain from baseline 6 months post procedure measured by the 11-point (0 = no pain, 10 is worst pain) Numerical Pain Rating Scale (NPRS).

6 months
Functional disability, measured by the Oswestry disability index (ODI)
大体时间:6 months

Difference in functional disability, measured by the Oswestry disability index (ODI) (0-100 scale, where 0 is no disability and 100 is bed bound), from baseline to 6 months post procedure.

6 months

次要结果测量

结果测量
措施说明
大体时间
Vertebral height difference (anterior, midline, and posterior aspects)
大体时间:Post-Operative, 1Month FU, 6 Months FU, 12 Months FU

Vertebral height difference (anterior, midline, and posterior aspects) at PO (Post-OP), 1M FU, 6M FU and 12M FU as compared to baseline.

Post-Operative, 1Month FU, 6 Months FU, 12 Months FU
Kyphotic angle and Cobb angle improvement at Post-Operative, 1 Month FU, 6 Months FU and 12 Months FU.
大体时间:Post-Operative, 1 Month FU, 6 Months FU and 12 Months FU.

Kyphotic angle and Cobb angle improvement

Post-Operative, 1 Month FU, 6 Months FU and 12 Months FU.
Vertebral fracture-related pain as assessed by the Numeric Pain Rating Scale (NPRS)
大体时间:Discharge, 1, 3, 6 and 12 Months FU compared to baseline.

Difference in vertebral fracture-related pain from baseline to Discharge, 1, 3, 6 and 12 Months post procedure measured by the 11-point (0 = no pain, 10 is worst pain) Numerical Pain Rating Scale (NPRS).

Discharge, 1, 3, 6 and 12 Months FU compared to baseline.
Functional disability, measured by the Oswestry disability index (ODI)
大体时间:Discharge, 1, 3, 6 and 12 months FU

Improvement in function (measured by the 100-point Oswestry Disability Index (ODI)) at discharge, 1, 3, 6 and 12 months FU compared to baseline.

Discharge, 1, 3, 6 and 12 months FU
Health-related quality of life (HRQoL) measured by EuroQol 5-Dimension Scale (EQ-5D-5L) at 1 Month, 3 Months, 6 Months and 12 Months post-procedure compared to baseline
大体时间:1 Month, 3 Months, 6 Months and 12 Months post-procedure compared to baseline

Improvement of Health-related quality of life (HRQoL)

1 Month, 3 Months, 6 Months and 12 Months post-procedure compared to baseline
Device-related serious adverse events assessed at 12- and 24- months post-procedure.
大体时间:12 months FU, 24 months FU

Device-related serious adverse events

12 months FU, 24 months FU
All (per protocol reportable) adverse events assessed at 12- and 24- months post-procedure.
大体时间:12 Months FU, 24 Months FU

All (per protocol reportable) adverse events assessed at 12- and 24- months post-procedure.

12 Months FU, 24 Months FU

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年10月4日

初级完成 (估计的)

2027年7月21日

研究完成 (估计的)

2028年12月31日

研究注册日期

首次提交

2026年7月31日

首先提交符合 QC 标准的

2026年11月4日

首次发布 (实际的)

2026年11月5日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅